Ongoing, recruitingTherapeutic exploratory (Phase II)Interventional

A Phase 2, Randomized, Open-Label, Study of Lorigerlimab with Docetaxel or Docetaxel Alone in Participants with Metastatic Castration-Resistant Prostate Cancer

At a glance

Status

Ongoing, recruiting

Phase

Therapeutic exploratory (Phase II)

Sponsor

Macrogenics Inc.

Enrolment target

Start

26 Sep 2023

Median radiographic progression free survival (rPFS) determined by investigator review.

Age 18 Years to any · Sex: Male

Always speak to your GP or specialist before deciding to take part in a study.